Keating G, Mitchell E A, Jackson R, Beaglehole R, Rea H
Br Med J (Clin Res Ed). 1984 Aug 11;289(6441):348-51. doi: 10.1136/bmj.289.6441.348.
As part of an investigation into the recent epidemic of deaths from asthma in New Zealand, trends in the sales of drugs for asthma in New Zealand, Australia, and the United Kingdom during 1975-81 were examined. Data on sales of drugs were obtained from an international pharmaceutical market research organisation. A striking increase in sales of sympathomimetic aerosols, steroid aerosols, and theophylline per caput occurred in all three countries, with the greatest increase occurring in New Zealand. Sales of sodium cromoglycate also increased in New Zealand and the UK but fell in Australia. By 1981 New Zealand had the highest sales of all these drugs per caput. Explanations for the rising mortality from asthma in New Zealand despite large increases in drug sales need to be explored. Although the temporal association between mortality and sales of drugs suggests that direct drug toxicity is unlikely, there may be more subtle adverse effects of drug use.
作为对新西兰近期哮喘死亡流行情况调查的一部分,研究了1975年至1981年期间新西兰、澳大利亚和英国哮喘药物的销售趋势。药物销售数据来自一家国际制药市场研究机构。在这三个国家,拟交感神经气雾剂、类固醇气雾剂和茶碱的人均销售额均显著增加,其中新西兰的增幅最大。色甘酸钠在新西兰和英国的销售额也有所增加,但在澳大利亚有所下降。到1981年,新西兰这些药物的人均销售额最高。尽管药物销售额大幅增加,但新西兰哮喘死亡率上升的原因仍需探究。虽然死亡率与药物销售之间的时间关联表明药物直接毒性不太可能,但药物使用可能存在更微妙的不良反应。